Drug Profile
Research programme: angiopoietin-2 inhibitors - Amgen
Alternative Names: L1-10Latest Information Update: 06 Apr 2011
Price :
$50
*
At a glance
- Originator Amgen
- Class Peptides
- Mechanism of Action Angiopoietin-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Apr 2009 Preclinical trials in Cancer in USA (unspecified route)